Search - tctmd.com

Displaying 1 - 20 of 65

Sort: Relevancy | Date

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

News Conference News ACC 2025

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

Michael O'Riordan

March 31, 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

March 30, 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

March 30, 2025

What’s Going to Be Hot at ACC 2025?

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

Another Win for TAVI in Low-to-Intermediate Risk Patients

News Conference News ACC 2024

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Yael L. Maxwell

April 08, 2024

TAVI, SAVR Rates Roughly Equal for Patients Younger Than 65 in New England

News Conference News ACC 2024

TAVI, SAVR Rates Roughly Equal for Patients Younger Than 65 in New England

Yael L. Maxwell

April 05, 2024

Real-world Primary MR TEER Outcomes Carry a Reminder: Do Better

News Conference News ACC 2023

Real-world Primary MR TEER Outcomes Carry a Reminder: Do Better

March 10, 2023

COAPT at 5 Years: MitraClip Still Ahead, but Deaths and Crossovers Cast Shadows

News Conference News ACC 2023

COAPT at 5 Years: MitraClip Still Ahead, but Deaths and Crossovers Cast Shadows

March 05, 2023

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

News Conference News ACC 2023

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

March 05, 2023

TRILUMINATE Pivotal: TEER With the TriClip Benefits Patients With Severe TR

News Conference News ACC 2023

TRILUMINATE Pivotal: TEER With the TriClip Benefits Patients With Severe TR

March 04, 2023

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

April 05, 2022

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

News Conference News ACC 2022

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

Yael L. Maxwell

April 05, 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

New HF Guidelines Stress Four Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 01, 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

March 28, 2022

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

Low 1-Year Stroke Risk After Commercial Watchman Use

News Conference News ACC 2021

Low 1-Year Stroke Risk After Commercial Watchman Use

May 15, 2021

Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III

News Conference News ACC 2021

Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III

May 15, 2021

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

News Conference News ACC 2020

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

April 07, 2020

New Patient-Focused TAVR Quality Score Rolling Out to US Hospitals

News Conference News ACC 2020

New Patient-Focused TAVR Quality Score Rolling Out to US Hospitals

Michael O'Riordan

April 06, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.